Clinical trials
Completed Observational Emphysema trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 1 |
| 2004 | 6 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 5 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 59 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Pittsburgh | 6 |
| Imperial College London | 5 |
| National Heart, Lung, and Blood Institute (NHLBI) | 5 |
| GlaxoSmithKline | 3 |
| Washington University School of Medicine | 3 |
| Weill Medical College of Cornell University | 3 |
| Columbia University | 2 |
| Adverum Biotechnologies, Inc. | 1 |
| Beijing Chao Yang Hospital | 1 |
| Children's Hospital of Eastern Ontario | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Emphysema | 59 |
| Pulmonary Disease, Chronic Obstructive | 46 |
| Bronchitis, Chronic | 13 |
| Lung Diseases | 8 |
| Asthma | 7 |
| Bronchitis | 6 |
| HIV Infections | 6 |
| Lung Diseases, Obstructive | 5 |
| Inflammation | 4 |
| alpha 1-Antitrypsin Deficiency | 4 |
Trials
Showing 1 to 25 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.